Biohaven
248 articles about Biohaven
-
Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder
10/24/2017
Biohaven and its wholly owned subsidiary, Biohaven Pharma, today announced that the FDA has notified the Company that it may proceed with its clinical investigation of trigriluzole, a novel glutamate modulator, as a potential treatment for patients with OCD.
-
Biohaven Tanks After Brain Disorder Drug Fails To Beat Placebo In Phase II/III Trial
10/2/2017
-
Biohaven And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase II Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease
9/15/2017
-
Biohaven Reports Second Quarter 2017 Financial And Business Results
8/14/2017
-
Biohaven Completes Randomization In Phase II/III Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017
8/7/2017
-
Biohaven Appoints Julia P. Gregory To Board Of Directors
8/4/2017
-
Biohaven Initiates Second Pivotal Phase III Clinical Trial Of Oral CGRP Antagonist For The Acute Treatment Of Migraine
7/31/2017
-
Biohaven Enrolls First Patient In Pivotal Phase III Clinical Trial Of Oral Rimegepant For The Acute Treatment Of Migraine
7/24/2017
-
Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs
7/13/2017
-
Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome
7/6/2017
-
Biohaven Added to Russell Microcap Index
6/26/2017
-
Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives
6/22/2017
-
Biohaven Reports First Quarter 2017 Financial and Business Results
6/16/2017
-
Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole
5/30/2017
-
Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA
5/15/2017
-
Biohaven Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
5/15/2017
-
Biohaven Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
5/12/2017
-
Portage Biotech's Holding In Biohaven
5/9/2017
-
Biohaven Announces Pricing of its Initial Public Offering of Common Shares
5/4/2017
-
Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC, Bristol-Myers Squibb Drugs
4/11/2017